No trace of sleeping pill was found in the box of Furosemide which had been implicated in Saint-Malo. The preliminary investigation opened in Paris was dismissed.
The testimony of the pharmacist of Saint-Malo who had assured to have found a sleeping pill in a blister of the diuretic Furosemide brought back by a client is again weakened! Recovered by investigators, this blister pack was subjected to analyzes chemicals, and no trace of Zopiclone was found. Result, lThe preliminary investigation opened in Paris into the alleged packaging error was closed without action for lack of infringement, the prosecutor’s office announced on Friday.
“None of the elements that came back to us made it possible to continue the investigation,” a spokesperson for the Paris prosecutor’s office told Agence Presse Médicale. So, does the alert launched by the pharmacist fall like a breath?
Possible, because the other reason for the discontinuation of this case is that all the results of the toxicological analyzes carried out within the framework of three of the six preliminary investigations opened after suspicious deaths were found to be negative. Moreover, for the Medicines Agency (Ansm) the question no longer even arises, itself having already sounded the end of the alert on June 20.
As a reminder, following this alert, two batches of the diuretic identified as problematic were first recalled, before all of the batches were withdrawn from the market. Very quickly, the Teva packaging site in Sens (Yonne), where Furosemide Teva and Zopiclone Teva were packaged, was searched. “This search also did not yield anything”, also indicates the spokesperson for the prosecution. The latter also added that the pharmacist and his assistant had been heard at the beginning of the week by the investigators, without providing more details.
Finally, as one can imagine, on the side of the pharmaceutical group Teva France, it is relief. The Israeli laboratory also welcomed in a statement released Friday evening the closure of the case. “The Sens production site is in no way involved in the so-called substitution,” he commented. Yet theAs always, the laboratory continues to defend the actions implemented following the alert launched by the pharmacist of Ille-et-Vilaine. “Teva recalls that the recall decision was taken within 24 hours, after six detailed and documented telephone conversations with the pharmacist who initiated this substitution alert. Teva felt, and still believes, that it was their responsibility to withdraw their drug from sale because patient safety is a priority, ”he concludes.
.
